Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2025 08:09 ET | Source: Crosetto Foundation for the Reduction of Cancer Deaths

Request for Secretary of State of Texas, Jane Nelson, to Organize a Public Meeting Between Crosetto and CPRIT Scientists Who Have Allocated $3.65 Billion of $6 Billion to Cancer Research

Request to Texas Secretary Jane Nelson: organize public meeting with Crosetto and CPRIT to ensure $6B cancer funds save lives and taxpayer money
August 18, 2025 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market ...
May 30, 2025 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Shareholder Update

May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline...
May 22, 2025 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to...
November 26, 2024 07:00 ET | Source: Eisbach Bio GmbH

Eisbach Bio Secures CPRIT Grant to Advance Novel Cancer Therapeutic

Eisbach Bio received a $4.75M award from the Cancer Prevention and Research Institute of Texas for clinical development of its novel allosteric inhibitor.
September 16, 2024 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant

September 16, 2024 Biodexa Pharmaceuticals PLC Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT GrantFunds to Advance Development of Phase 3 Asset ...
July 23, 2024 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)...
June 03, 2024 12:57 ET | Source: 7 Hills Pharma

7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic

Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases
April 26, 2024 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...
May 22, 2023 13:05 ET | Source: 7 Hills Pharma

7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding

HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...